Mounjaro (Tirzepatide)

Tirzepatide activates both GIP and GLP‑1 receptors, which enhances insulin secretion in response to glucose, suppresses glucagon release, slows gastric emptying, and reduces appetite, thereby lowering blood sugar levels and supporting weight loss.

The dose of Mounjaro is individualized by a qualified prescriber based on the patient’s clinical condition, response, and any concomitant therapies. Patients should follow the dosing schedule provided by their healthcare professional.

The safety of tirzepatide in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by the prescribing clinician.

To request Mounjaro, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and the necessary import documentation.

Mounjaro is unique as a dual GIP and GLP‑1 receptor agonist, offering both glucose‑lowering and weight‑loss benefits. Compared with single‑target GLP‑1 analogues, tirzepatide may provide greater reductions in HbA1c and body weight, though individual response and tolerability can vary.

Mounjaro should be stored in a refrigerator at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability.

Mounjaro is supplied as a solution for injection and is administered subcutaneously, typically in the abdomen, thigh, or upper arm. The injection is given once weekly, and patients should be trained by a healthcare professional on proper technique.

Serious risks include pancreatitis, severe hypoglycemia (especially when combined with insulin or sulfonylureas), gallbladder disease, allergic reactions such as anaphylaxis, and, based on animal data, a potential risk of thyroid C‑cell tumors. Patients should be monitored for symptoms of these conditions.

Mounjaro is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, and it should be avoided in patients with known hypersensitivity to tirzepatide or any of the formulation components.